Voyager Therapeutics, Inc. (NASDAQ:VYGR) Short Interest Up 28.9% in April

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Rating) saw a large growth in short interest in April. As of April 15th, there was short interest totalling 1,240,000 shares, a growth of 28.9% from the March 31st total of 962,300 shares. Approximately 4.8% of the company’s stock are short sold. Based on an average daily volume of 806,300 shares, the days-to-cover ratio is currently 1.5 days.

Voyager Therapeutics stock opened at $7.33 on Monday. Voyager Therapeutics has a 52 week low of $2.46 and a 52 week high of $10.60. The company’s 50 day moving average price is $7.12 and its two-hundred day moving average price is $4.59. The stock has a market cap of $281.49 million, a P/E ratio of -3.86 and a beta of 1.13.

Voyager Therapeutics (NASDAQ:VYGR – Get Rating) last posted its earnings results on Tuesday, March 8th. The company reported $0.15 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.51. Voyager Therapeutics had a negative net margin of 190.30% and a negative return on equity of 66.35%. The firm had revenue of $28.07 million for the quarter, compared to analysts’ expectations of $31.45 million. As a group, sell-side analysts expect that Voyager Therapeutics will post -1.35 EPS for the current fiscal year.

In other news, VP Robert W. Hesslein sold 4,955 shares of the stock in a transaction dated Monday, March 21st. The shares were sold at an average price of $8.29, for a total transaction of $41,076.95. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Robin Swartz sold 4,413 shares of the stock in a transaction dated Monday, March 21st. The stock was sold at an average price of $8.29, for a total transaction of $36,583.77. The disclosure for this sale can be found here. Insiders have sold a total of 16,933 shares of company stock worth $124,170 in the last three months. Insiders own 25.40% of the company’s stock.

Several institutional investors have recently bought and sold shares of VYGR. Royal Bank of Canada lifted its position in shares of Voyager Therapeutics by 160.7% during the 2nd quarter. Royal Bank of Canada now owns 5,937 shares of the company’s stock worth $25,000 after buying an additional 3,660 shares in the last quarter. Focused Wealth Management Inc bought a new stake in shares of Voyager Therapeutics in the 4th quarter worth approximately $27,000. Virtu Financial LLC bought a new stake in shares of Voyager Therapeutics in the 4th quarter worth approximately $28,000. Koss Olinger Consulting LLC bought a new stake in shares of Voyager Therapeutics in the 4th quarter worth approximately $54,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Voyager Therapeutics in the 4th quarter worth approximately $56,000. 63.55% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts recently weighed in on VYGR shares. Chardan Capital upped their target price on shares of Voyager Therapeutics from $4.00 to $6.00 in a report on Wednesday, March 9th. Zacks Investment Research upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Saturday, March 12th. UBS Group lowered their target price on shares of Voyager Therapeutics from $14.00 to $6.00 in a report on Monday, January 3rd. Finally, StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Voyager Therapeutics has a consensus rating of “Buy” and a consensus target price of $13.67.

Voyager Therapeutics Company Profile (Get Rating)

Voyager Therapeutics, Inc, a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.

Further Reading